Basilea Pharmaceutica AG (BSLN) — Cash Flow Quality Index
Basilea Pharmaceutica AG (BSLN) has a Cash Flow Quality Index of 1.60x as of December 2025. Operating cash flow of CHF39.03 Million exceeds net income of CHF24.44 Million, indicating high earnings quality where cash backs reported profits. Explore BSLN cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Basilea Pharmaceutica AG Cash Flow Quality Index (2010–2025)
Historical Cash Flow Quality Index for Basilea Pharmaceutica AG across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see how efficiently does Basilea Pharmaceutica AG generate cash.
Annual Cash Flow Quality Index for Basilea Pharmaceutica AG (2010–2025)
Year-by-year earnings quality comparison for Basilea Pharmaceutica AG.
| Year | Quality Index | Operating CF (CHF) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.54x | CHF62.09 Million | CHF40.24 Million | ▲ +61.0% |
| 2024 | 0.96x | CHF74.36 Million | CHF77.59 Million | ▼ -29.7% |
| 2023 | 1.36x | CHF14.24 Million | CHF10.45 Million | ▲ +134.6% |
| 2022 | 0.58x | CHF7.06 Million | CHF12.15 Million | ▼ -41.4% |
| 2010 | 0.99x | CHF106.64 Million | CHF107.56 Million | — |